ADVERTISEMENT
site_logo
  • Campus
  • Happening
  • Opinion
  • People
  • News
  • #BeInspired
  • Careers
  • 40 under 40
  • Exams
  • What The FAQ
  • Videos
    • Straight Up
    • Odisha Literary Festival 2020
    • Campus Convo
    • Careers After Corona
    • Express Expressions
    • Q&A With Prabhu Chawla
    • ThinkEdu Awards 2020
  • edex_worksEDEXWORKS
ADVERTISEMENT
Vaccine

Published: 22nd December 2020     

Bharat Biotech recruits 13,000 volunteers for Covaxin Phase III trials

The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers across India

Edex Live
Edex Live
f_icon t_icon i_icon l_icon koo_icon whatsapp_icon email_icon

Share Via Email

vaccine

Representational image (Source: PTI)

Bharat Biotech on Tuesday announced successful recruitment of 13,000 volunteers, and continued progress towards achieving the goal of 26,000 participants for Phase III clinical trial of its coronavirus vaccine Covaxin across multiple sites in India.

The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers across India. Suchitra Ella, Joint Managing Director of Bharat Biotech termed this as an unprecedented vaccine trial ever in India. She said they were overwhelmed with the steady rise in participation. "We sincerely thank all the 13,000 volunteers across the country for their support in enabling us to bring out a safe and efficacious Indian vaccine for COVID-19. This pro-vaccine public health volunteerism is a morale booster for us to achieve our milestone target of 26,000 soon."

This is India's first and only Phase III efficacy study for a COVID-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India. Covaxin has been evaluated in approximately 1,000 subjects in Phase I and Phase II clinical trials, with promising safety and immunogenicity results, with acceptance in international peer-reviewed scientific journals, the Hyderabad-based company said.

Covaxin, India's indigenous Covid-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) -- National Institute of Virology (NIV). This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world.

Covaxin is a highly purified and inactivated 2 dose SARS-CoV2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than 300 million doses.

telegram
TAGS
Vaccine Covaxin

O
P
E
N

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
telegram
ADVERTISEMENT
Write to us!

If you have campus news, views, works of art, photos or just want to reach out to us, just drop us a line.

newsletter_icon
Mailbox
edexlive@gmail.com
fb_icon
Facebook
twitter_icon
Twitter
insta_icon
Instagram
ADVERTISEMENT
Facebook
ADVERTISEMENT
Tweets by Xpress_edex
ADVERTISEMENT
ADVERTISEMENT

FOLLOW US

Copyright - edexlive.com 2021

The New Indian Express | Dinamani | Kannada Prabha | Samakalika Malayalam | Indulgexpress | Cinema Express | Event Xpress

Contact Us | About Us | Privacy Policy | Terms of Use | Advertise With Us

Home | Live Now | Live Story | Campus Trip | Coach Calling | Live Take